PURPOSE: To report on the 15-year prostate cancer experience of our multidisciplinary genitourinary cancer clinic established in 1996 at the National Cancer Institute (NCI) -designated Jefferson Kimmel Cancer Center. Patients with genitourinary cancers were evaluated weekly by multiple specialists at a single site, and we focus on the 83% of patients with prostate cancer. To our knowledge, our multidisciplinary genitourinary cancer clinic is the longest continuously operating center of its kind at an NCI Cancer Center in the United States. METHODS: Data from Jefferson's Oncology Data Services were compared to SEER prostate cancer outcomes. Data on treatment changes in localized disease, patient satisfaction, and related parameters were also assessed. RESULTS: Ten-year survival data approach 100% in stage I and II prostate cancer. Ten-year data for stage III (T3 N0M0) and stage IV (T4 N0M0) disease show that our institutional survival rate exceeds SEER. There is a shift toward robotically assisted laparoscopic radical prostatectomy and a slight decrease in brachytherapy relative to external beam radiation therapy in localized disease. Patient satisfaction is high as measured by survey instruments. CONCLUSION: Our long-term experience suggests a benefit of the multidisciplinary clinic approach to prostate cancer, most pronounced for high-risk, locally advanced disease. A high level of satisfaction with this patient-centered model is seen. The multidisciplinary clinic approach to prostate cancer may enhance outcomes and possibly reduce treatment regret through a coordinated presentation of all therapeutic options. This clinic model serves as an interdisciplinary educational tool for patients, their families, and our trainees and supports clinical trial participation.
PURPOSE: To report on the 15-year prostate cancer experience of our multidisciplinary genitourinary cancer clinic established in 1996 at the National Cancer Institute (NCI) -designated Jefferson Kimmel Cancer Center. Patients with genitourinary cancers were evaluated weekly by multiple specialists at a single site, and we focus on the 83% of patients with prostate cancer. To our knowledge, our multidisciplinary genitourinary cancer clinic is the longest continuously operating center of its kind at an NCI Cancer Center in the United States. METHODS: Data from Jefferson's Oncology Data Services were compared to SEER prostate cancer outcomes. Data on treatment changes in localized disease, patient satisfaction, and related parameters were also assessed. RESULTS: Ten-year survival data approach 100% in stage I and II prostate cancer. Ten-year data for stage III (T3 N0M0) and stage IV (T4 N0M0) disease show that our institutional survival rate exceeds SEER. There is a shift toward robotically assisted laparoscopic radical prostatectomy and a slight decrease in brachytherapy relative to external beam radiation therapy in localized disease. Patient satisfaction is high as measured by survey instruments. CONCLUSION: Our long-term experience suggests a benefit of the multidisciplinary clinic approach to prostate cancer, most pronounced for high-risk, locally advanced disease. A high level of satisfaction with this patient-centered model is seen. The multidisciplinary clinic approach to prostate cancer may enhance outcomes and possibly reduce treatment regret through a coordinated presentation of all therapeutic options. This clinic model serves as an interdisciplinary educational tool for patients, their families, and our trainees and supports clinical trial participation.
Authors: Thomas L Jang; Justin E Bekelman; Yihai Liu; Peter B Bach; Ethan M Basch; Elena B Elkin; Michael J Zelefsky; Peter T Scardino; Colin B Begg; Deborah Schrag Journal: Arch Intern Med Date: 2010-03-08
Authors: R K Valicenti; L G Gomella; E A El-Gabry; R Myers; F Nathan; S Strup; A Dicker; D E McGinnis; G Cardi; M Baltish; M Simirgliano; A Vizzard; S G Mulholland Journal: Semin Urol Oncol Date: 2000-08
Authors: G Pichert; C Jacobs; I Jacobs; U Menon; R Manchanda; M Johnson; H Hamed; C Firth; M Evison; A Tutt; L de Silva; C Langman; L Izatt Journal: Fam Cancer Date: 2010-09 Impact factor: 2.375
Authors: Benjamin D Sommers; Clair J Beard; Anthony V D'Amico; Irving Kaplan; Jerome P Richie; Richard J Zeckhauser Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: Jane L Hudak; David G McLeod; Stephen A Brassell; Dean A Gant; Stephanie Shaar; Ronald P Hudak; Robert C Dean; Mary D McGarvey; Steven J Tulin; Raziya Dozier Journal: Urol Nurs Date: 2007-12
Authors: Jim C Hu; Lorna Kwan; Tracey L Krupski; Jennifer T Anger; Sally L Maliski; Sarah Connor; Mark S Litwin Journal: Urology Date: 2008-03-03 Impact factor: 2.649
Authors: Räto T Strebel; Tullio Sulser; Hans-Peter Schmid; Silke Gillessen; Martin Fehr; Urs Huber; Miklos Pless; Rudolf Morant; Ralph Winterhalder; Richard Cathomas Journal: Support Care Cancer Date: 2013-03-26 Impact factor: 3.603
Authors: Ronald E Myers; Amy E Leader; Jean Hoffman Censits; Edouard J Trabulsi; Scott W Keith; Anett M Petrich; Anna M Quinn; Robert B Den; Mark D Hurwitz; Costas D Lallas; Sarah E Hegarty; Adam P Dicker; Charnita M Zeigler-Johnson; Veda N Giri; Hasan Ayaz; Leonard G Gomella Journal: J Cancer Educ Date: 2018-02 Impact factor: 2.037
Authors: Christoph Kowalski; Julia Ferencz; Peter Albers; Jan Fichtner; Thomas Wiegel; Günter Feick; Simone Wesselmann Journal: World J Urol Date: 2015-09-21 Impact factor: 4.226
Authors: Eberechukwu Onukwugha; Nicholas J Petrelli; Kathleen M Castro; James F Gardner; Jinani Jayasekera; Olga Goloubeva; Ming T Tan; Erica J McNamara; Howard A Zaren; Thomas Asfeldt; James D Bearden; Andrew L Salner; Mark J Krasna; Irene Prabhu Das; Steve B Clauser; Eberechukwu Onukwugha; Nicholas J Petrelli; Kathleen M Castro; James F Gardner; Jinani Jayasekera; Olga Goloubeva; Ming T Tan; Erica J McNamara; Howard A Zaren; Thomas Asfeldt; James D Bearden; Andrew L Salner; Mark J Krasna; Irene Prabhu Das; Steve B Clauser Journal: J Oncol Pract Date: 2015-10-13 Impact factor: 3.840
Authors: Thomas M Churilla; Brian L Egleston; Colin T Murphy; Elin R Sigurdson; Shelly B Hayes; Lori J Goldstein; Richard J Bleicher Journal: Breast Cancer Res Treat Date: 2016-09-17 Impact factor: 4.872
Authors: Lauren C Harshman; Abhishek Tripathi; Matthew Kaag; Jason A Efstathiou; Andrea B Apolo; Jean H Hoffman-Censits; Walter M Stadler; Evan Y Yu; Bernard H Bochner; Eila C Skinner; Tracy Downs; Anne E Kiltie; Dean F Bajorin; Khurshid Guru; William U Shipley; Gary D Steinberg; Noah M Hahn; Srikala S Sridhar Journal: Clin Genitourin Cancer Date: 2017-12-06 Impact factor: 2.872
Authors: J Zhang; M N Mavros; D Cosgrove; K Hirose; J M Herman; S Smallwood-Massey; I Kamel; A Gurakar; R Anders; A Cameron; J F H Geschwind; T M Pawlik Journal: Curr Oncol Date: 2013-04 Impact factor: 3.677